Windward Bio (WWB.US) seeks to raise up to $100 million in US IPO; multiple drugs licensed from Chinese pharmaceutical companies.

Zhitong Finance APP has learned that Windward Bio Group, a Switzerland-based clinical-stage biotechnology company, submitted an initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) last Friday, seeking to raise up to $100 million.